Related Experiment Videos
Papillomavirus virus-like particles as anticancer vaccines
D M Da Silva1, M P Velders, M P Rudolf
1Cardinal Bemardin Cancer Center & Department of Microbiology & Immunology, Loyola University, Chicago, 2160 S First Avenue, Maywood, IL 60153, USA.
Current Opinion in Molecular Therapeutics
|March 16, 2001
Summary
Chimeric human papillomavirus (HPV) virus-like particles (VLPs) show promise as vaccines. These VLPs effectively stimulate immune responses for both preventing and treating HPV-induced lesions and tumors.
Area of Science:
- Immunology
- Vaccinology
- Virology
Background:
- Virus-like particles (VLPs) are non-infectious structures that mimic viral pathogens.
- Human papillomavirus (HPV) VLPs are crucial for developing vaccines against HPV infections.
- Chimeric HPV VLPs incorporate additional viral proteins for enhanced vaccine strategies.
Purpose of the Study:
- To review advancements in chimeric HPV VLP production.
- To summarize the immune responses elicited by HPV VLPs and chimeric VLPs.
- To assess the potential of VLPs in generating antitumor immune responses.
Main Methods:
- Production of chimeric HPV VLPs.
- Analysis of humoral and cellular immune responses in preclinical models.
- Evaluation of VLP-induced immune memory and effector functions.
Main Results:
- HPV VLPs and chimeric VLPs induce potent antibody and T-cell responses.
- Chimeric VLPs demonstrate potential for combined prophylactic and therapeutic applications.
- VLPs prime CD8+ T-cells and activate cytotoxic T-cell responses.
Conclusions:
- Chimeric HPV VLPs represent a promising platform for next-generation vaccines.
- VLPs can generate robust immune responses for protection and therapy against HPV.
- Further research into VLP technology may lead to novel cancer immunotherapies.